Literature DB >> 6333840

Antimicrobial therapy of experimentally induced Legionnaires' disease in guinea pigs.

P H Edelstein, K Calarco, V K Yasui.   

Abstract

A guinea pig model of Legionnaires' disease was produced by intratracheal inoculation of Legionella pneumophila. The bacterial inoculum given reproducibly resulted in a 95% fatality rate in untreated animals. These animals had lung histopathologic and bacteriologic findings almost identical to those found in human Legionnaires' disease. Administration of cefoxitin and gentamicin, which inhibited the infecting strain in low antibiotic concentration in vitro, was no more effective than saline; this occurred despite adequate serum and lung levels of the drugs. Erythromycin, rifampin, doxycycline, and cotrimoxazole significantly reduced fatality rates. The combinations of erythromycin with rifampin and doxycycline with rifampin were not significantly better or worse than use of either drug alone. In animals treated with any regimen containing rifampin, a dramatically higher rate of bacterial killing was observed than that observed in those animals treated with erythromycin or doxycycline alone. Also, animals treated with any regimen containing rifampin had significantly less late lung histologic evidence of pneumonia than did those treated with other agents. No rifampin-induced resistance was found. This animal model reflects prior clinical findings, provides experimental grounds for therapy with drugs other than erythromycin, and suggests that therapy of Legionnaires' disease should probably include rifampin in most cases.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6333840     DOI: 10.1164/arrd.1984.130.5.849

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  33 in total

1.  In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein; J Weidenfeld; M B Dorr
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

3.  Discovery of virulence genes of Legionella pneumophila by using signature tagged mutagenesis in a guinea pig pneumonia model.

Authors:  P H Edelstein; M A Edelstein; F Higa; S Falkow
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

4.  Simplified quantitative assay system for measuring activities of drugs against intracellular Legionella pneumophila.

Authors:  F Higa; N Kusano; M Tateyama; T Shinzato; N Arakaki; K Kawakami; A Saito
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

5.  Legionnaires' disease: a review of 79 community acquired cases in Nottingham.

Authors:  M A Woodhead; J T Macfarlane
Journal:  Thorax       Date:  1986-08       Impact factor: 9.139

6.  Precision and accuracy of recovery of Legionella pneumophila from seeded tap water by filtration and centrifugation.

Authors:  C A Boulanger; P H Edelstein
Journal:  Appl Environ Microbiol       Date:  1995-05       Impact factor: 4.792

7.  Potential virulence role of the Legionella pneumophila ptsP ortholog.

Authors:  F Higa; P H Edelstein
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

8.  In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species.

Authors:  P H Edelstein; M A Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages.

Authors:  D A Stamler; M A Edelstein; P H Edelstein
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

Review 10.  Treatment of Legionnaires' disease. Current recommendations.

Authors:  J Roig; A Carreres; C Domingo
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.